Effects of omalizumab in Aspergillus-associated airway disease

Pérez-de-Llano, Luis; Vennera, María del Carmen; Parra, Antonio; Guallar, Joan Pérez; Marín, Manuel Salvador; Asensio, Òscar; Ausín, Pilar; Borderías, Luis; Fernández, Carmen Jiménez; Granel, C; Pérez-Pimiento, A; Rubio, M.

doi:10.1136/thx.2010.153312

Cited by 51 publications

(43 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Omalizumab-treated ABPA patients reported in the literature have generally responded well, with reduced exacerbation rates, decreased oral steroid exposure and decreased steroid toxicity being the three major observed benefits of therapy [127][128][129][130][131][132][133][134][135][136][137][138][139][140][141][142]. For example, two openlabelled series from Spain and France (34 subjects when pooled, including two with CF-ABPA) showed significant reductions in exacerbations and oral steroid doses [137,138]. However, a recent multicentre open-labelled retrospective series from France found variable results over an average 21-month observation period in 32 CF-ABPA patients on omalizumab, with a reduction in steroid need but no change in lung function or use of i.v.…”

Section: Anti-igementioning

confidence: 99%

Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis

Moss

2013

Eur Respir J

View full text Add to dashboard Cite

Severe asthma with fungal sensitisation and allergic bronchopulmonary aspergillosis encompass two closely related subgroups of patients with severe allergic asthma. Pulmonary disease is due to pronounced host inflammatory responses to noninvasive subclinical endobronchial infection with filamentous fungi, usually Aspergillus fumigatus. These patients usually do not achieve satisfactory disease control with conventional treatment of severe asthma, i.e. high-dose inhaled corticosteroids and long-acting bronchodilators. Although prolonged systemic corticosteroids are effective, they carry a substantial toxicity profile. Supplementary or alternative therapies have primarily focused on use of antifungal agents including oral triazoles and inhaled amphotericin B. Immunomodulation with omalizumab, a humanised anti-IgE monoclonal antibody, or "pulse" monthly high-dose intravenous corticosteroid, has also been employed. This article considers the experience with these approaches, with emphasis on recent clinical trials. @ERSpublications Treatment of fungal asthma includes glucocorticoids, azoles, amphotericin and anti-IgE. Trial validation is needed.

show abstract

Section: Anti-igementioning

confidence: 99%

Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis

Moss

2013

Eur Respir J

View full text Add to dashboard Cite

show abstract

“…In addition, a reduction in the usage of oral corticosteroids was noted. Recent studies in patients with ABPA due to underlying asthma also demonstrated statistically significant symptom control, reduction in eosinophilia and total IgE levels, improved FEV1, fewer asthma exacerbations and decreased usage of oral corticosteroids after appropriate therapy with omalizumab [169][170][171]. This drug could possibly have the potential to emerge as a steroid-sparing alternative in a select subset of patients who continue to remain corticosteroid dependent (stage 4).…”

Section: Omalizumabmentioning

confidence: 97%

Allergic aspergillosis of the respiratory tract

Shah

Panjabi

2014

Eur Respir Rev

View full text Add to dashboard Cite

“…Several case series has been reported of successful therapy with omalizumab in ABPA patients without CF [29][30][31][32][33]. AntiIgE therapy produced steroid-sparing effect, reduced systemic inflammatory markers, and resulted in improvement in ACT scores in patients with ABPA.…”

Section: Allergic Bronchopulmonary Aspergillosismentioning

confidence: 99%

Off-Label Uses of Omalizumab

El-Qutob¹

2015

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

The off-label use of medicines is a common and extensive clinical practice. Omalizumab has been licensed for use in severe allergic asthma and chronic urticaria. Omalizumab dosing was based on body weight and baseline serum IgE concentration. All patients are required to have a baseline IgE between 30 and 700 IU/ml and body weight not more than 150 kg. The use of off-label drugs may lead to several problems including adverse effects and an increased risk/benefit balance. In this article, there are summarized off-label uses of omalizumab in the last recent years in diseases in which IgE maybe or certainly has a corner role such as allergic rhinitis, allergic bronchopulmonary aspergillosis, anaphylaxis, keratoconjunctivitis, food allergy, drug allergy, urticaria, angioedema, non-atopic asthma, atopic dermatitis, nasal polyps, Churg-Strauss syndrome, eosinophilic otitis media, chronic rhinosinusitis, bullous pemphigoid, contact dermatitis, and others. Use in pregnancy asthmatic women and pre-co-administration with specific immunotherapy will also be revised.

show abstract

Effects of omalizumab in Aspergillus-associated airway disease

Cited by 51 publications

References 7 publications

Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis

Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis

Allergic aspergillosis of the respiratory tract

Off-Label Uses of Omalizumab

Contact Info

Product

Resources

About